
Opinion|Videos|June 16, 2025
Improving diversity in future clinical trials for mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Enhancing diversity in mHSPC clinical trials requires community outreach, collaboration, and accessible care for underrepresented populations.
Advertisement
Episodes in this series

Improving Clinical Trial Diversity
Key Themes:
- A multistakeholder approach is required (patients, communities, clinicians, payers, industry).
- Community outreach initiatives are essential for building trust.
- A comprehensive approach is needed to address the barriers to participation.
- Bring clinical trial access directly into communities of color.
Key Points for Physicians:
- Support or participate in community outreach programs.
- Address practical barriers to clinical trial participation with patients.
- Consider geographical and logistical factors when referring patients to trials.
- Recognize the importance of building trust through community engagement.
Notable Insights: Creating direct conduits to high-quality care through community-based initiatives represents a practical strategy for improving trial diversity and addressing historical mistrust.
Clinical Significance: Systematic approaches to improving trial diversity are essential for generating evidence applicable to all patient populations and addressing historical health care disparities.
Advertisement
Related to this article

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5


